Matches in DBpedia 2016-04 for { ?s ?p "GlySens, a biomedical technology company, is a privately owned corporation developing a long term internal continuous glucose monitor in order to effectively manage and observe glucose levels in real-time.The GlySens ICGM system is the world's first surgically implanted CGM system to demonstrate an 18-month performance in a preclinical setting. GlySens Incorporated was founded in1998 by David A. Gough and Joseph Lucisano, a UCSD Bioengineering graduate. The ICGM system uses an internal sensor equipped with electro-chemical detectors to measure glucose readings via a chemical reaction between enzymes and oxygen. With an expected release in 2016, the GlySens ICGM will be the first publicly available glucose monitor capable of withstanding 12+ months of continual use. As the global population of diabetics approached 400 million, this device can dramatically improve the quality of diabetic care."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- GlySens_ICGM abstract "GlySens, a biomedical technology company, is a privately owned corporation developing a long term internal continuous glucose monitor in order to effectively manage and observe glucose levels in real-time.The GlySens ICGM system is the world's first surgically implanted CGM system to demonstrate an 18-month performance in a preclinical setting. GlySens Incorporated was founded in1998 by David A. Gough and Joseph Lucisano, a UCSD Bioengineering graduate. The ICGM system uses an internal sensor equipped with electro-chemical detectors to measure glucose readings via a chemical reaction between enzymes and oxygen. With an expected release in 2016, the GlySens ICGM will be the first publicly available glucose monitor capable of withstanding 12+ months of continual use. As the global population of diabetics approached 400 million, this device can dramatically improve the quality of diabetic care.".